The latest biotech news

News and Trends 2 Nov 2022

Meletios Therapeutics wins €5.2M European Commission funding for SARS research

Meletios Therapeutics, a French biotech company, announced today (November 2) that it has been named one of 75 winners of the European Innovation Council (EIC) Accelerator program and will receive €5.2 million ($5.1 million) in funding from the European Commission. The company specializes in the research and development of antiviral treatments and says the funding […]

November 2, 2022 - 3 minutesmins - By Liza Laws

News and Trends 2 Nov 2022

CV6 Therapeutics raises $9.2M to test cancer drug

CV6 Therapeutics has secured $9.2m to progress its lead oncology asset, CV6-168, into a first-in-human phase 1a clinical trial and perform further scientific development work. CV6 Therapeutics is a drug development biotechnology company specializing in innovative small molecule therapeutics for cancer and inflammatory diseases. Investors participating in the financing include QUBIS, the commercialization arm of […]

November 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 2 Nov 2022

Alkermes to separate oncology business

Alkermes plc is to explore separating its commercial-stage neuroscience business and development-stage oncology business. The company, its board and external financial and legal advisors plan to explore a separation of the oncology business into an independent, publicly-traded company (Oncology Co.) as part of an ongoing review of strategic alternatives for the oncology business. Alkermes said […]

November 2, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 2 Nov 2022

New therapeutic strategy to improve treatment of aggressive endometrial cancer

Endometrial cancer (EC) is the most common type of gynecological cancer and is the fourth most common type of tumor in women in developed countries. Although it has a good prognosis if detected early, advanced and aggressive cases have a high mortality rate and are often resistant to standard chemotherapy treatments. Now, a study published […]

November 2, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 2 Nov 2022

The Native Antigen Company expands range of Omicron antigens to include BA.5 variant

The Native Antigen Company today (November 2) announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant. The company, part of LGC Clinical Diagnostics, is a supplier of reagents enabling research into vaccines and diagnostics for emerging endemic infectious diseases. The new range of RBD (receptor binding domain) antigens […]

November 2, 2022 - 2 minutesmins - By Liza Laws

News and Trends 2 Nov 2022

AELIX Therapeutics publishes positive data on its HIV vaccine

Positive results from a clinical study into biotech company, AELIX’ Therapeutics’, HIV vaccine have been published in Nature Medicine journal. The announcement came today (November 2) from the Spanish-based company that specializes in developing immunotherapies for HIV infection. Christian Brander, co-founder and chief scientific officer at AELIX, said: “We are excited to have published the […]

November 2, 2022 - 3 minutesmins - By Liza Laws

News and Trends 2 Nov 2022

Enzyre secures €12M series A funding to help hemophilia patients test from home

Dutch company, Enzyre, which is developing ambulant diagnostic technology for blood coagulation testing, today (November 2) announced it has successfully raised €12 million ($11.9 million) in series A financing. The round was led by new investor, Oost NL, with participation from i&i Biotech Fund, Demcon Investment as technology partner and existing investors, Takeda Ventures and […]

November 2, 2022 - 3 minutesmins - By Liza Laws

News and Trends 2 Nov 2022

Could DNA nanotransporters treat cancer?

A team of Canadian researchers from Université de Montréal has designed and validated a new class of drug transporters made of DNA 20,000 times smaller than a human hair. The DNA nanotransporters could improve how cancers and other diseases are treated. Reported in a new study in Nature Communications, the molecular transporters can be chemically […]

November 2, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 1 Nov 2022

Avista Capital Partners acquires Taconic Biosciences

Private equity company Avista Capital Partners has acquired Taconic Biosciences, a provider of genetically engineered research models (GEMs) and related services, from H.I.G. Capital. Transaction terms were not disclosed. Founded in 1952 and headquartered in Rensselaer, N.Y., Taconic Biosciences specializes in genetically engineered research models and services, specifically murine models for use in drug discovery […]

November 1, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 1 Nov 2022

Proscia presents results on AI melanoma diagnostic predictions

Proscia has released study results on new artificial intelligence (AI) that predicts diagnostic agreement for melanoma, the deadliest form of skin cancer. The findings, presented at the European Conference on Computer Vision (ECCV) 2022, highlight the potential of the technology to improve diagnostic accuracy for melanoma and other diseases with low pathologist concordance. Conducted at […]

November 1, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 1 Nov 2022

J.P. Morgan launches life sciences private capital team

J.P. Morgan Asset Management has announced the launch of a new life sciences private equity team, Life Sciences Private Capital. The new team will invest in early and growth stage healthcare companies across multiple strategies aligned to specific market opportunities, with a focus on novel therapeutics and technologies in several target areas. These include genetic […]

November 1, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 1 Nov 2022

First to market doesn’t guarantee success

A comparison of two cancer drugs, Opdivo and Keytruda, reveals that being the first-to-market is not necessarily the main factor in a drug’s success. For the first four years since their approval, the anticancer drug Opdivo outperformed Keytruda in sales. But this trend reversed in 2018, with Keytruda’s sales becoming higher than Opdivo’s. Recently, a […]

November 1, 2022 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Meletios Therapeutics wins €5.2M European Commission funding for SARS research

CV6 Therapeutics raises $9.2M to test cancer drug

Alkermes to separate oncology business

New therapeutic strategy to improve treatment of aggressive endometrial cancer

The Native Antigen Company expands range of Omicron antigens to include BA.5 variant

AELIX Therapeutics publishes positive data on its HIV vaccine

Enzyre secures €12M series A funding to help hemophilia patients test from home

Could DNA nanotransporters treat cancer?

Avista Capital Partners acquires Taconic Biosciences

Proscia presents results on AI melanoma diagnostic predictions

J.P. Morgan launches life sciences private capital team

First to market doesn’t guarantee success

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!